Advanced Filters
noise

Villeurbanne, France Clinical Trials

A listing of Villeurbanne, France clinical trials actively recruiting patients volunteers.

Found 796 clinical trials
J Jacques-Olivier BAY, Pr

French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T)

This study is a registry including prospective and retrospective data on all patients who have been presented in a Multidisciplinary tumor board or RCP to be eligible for CAR-T cell treatment.

- 99 years of age All Phase N/A
M Martina Piccini, MD

Observational Study, for Quality Assessment, of Sarcoma in European and Latin American Multidisciplinary NETWORK

Post-authorisation, multicentric, observational, retrospective and prospective study to assess quality of care of sarcoma patients in expert and non-expert centers by analysing correlation of quality items and outcomes such as relapse free survival, overall survival, percentage of amputation, etc. Expert pathology peer review will be performed to detect differences between …

18 - 120 years of age All Phase N/A

Dat'Aids Prevention

DatAIDS prevention is a cohort study of HIV prevention in over 23 HIV sites in France including overseas, aiming to describe HIV prevention in every aspect including HIV screening, STI and hepatitis screening, post-exposure prophylaxis and pre-exposure prophylaxis

18 years of age All Phase N/A
B Boston Scientific Clinical Research

Patient Retrospective Outcomes (PRO)

This study will evaluate de-identified (anonymous) data in subject medical charts to review the clinical outcomes of various treatment approaches in the treatment of chronic pain.

18 years of age All Phase N/A
S Sandra VUKUSIC, MD

French Registry for Monitoring Pregnancies for Multiple Sclerosis

The influence of pregnancy on the course of multiple sclerosis (MS) has long been a controversial topic. After the publication of the first large prospective study of pregnancy and MS in 1998, counselling of women with MS has radically changed and many patients have been able to fulfill their desire …

years of age All Phase N/A
M Marco Spinazzi, MD

Observatoire Des Patients Atteints de Laminopathies et Emerinopathies (Observatory for PAtients With Laminopathies and Emerinopathies)

Laminopathies and emerinopathies are complex group of rare disorders due to mutations in A-type lamins (LMNA) and Emerin (EMD) genes. Among them, disorders affecting skeletal and/or cardiac muscles are the most frequent clinical manifestations, with cardiac disease being a major cause of death. Remarkable progress has been made in the …

years of age All Phase N/A

Qualitative Analysis of Interviews Between Pharmacist and Elderly Patients Treated With Antithrombotics for an Ischemic Stroke.

Cerebrovascular accident is the 2nd leading cause of death and the leading cause of disability in the world. There are brakes and levers of medication adherence in the context of secondary prevention treatment in stroke.

65 - 100 years of age All Phase N/A
B Bénédicte DEAU FISCHER, MD

Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Registry

Anaplastic large cell lymphoma associated with breast implants (BIA-ALCL) is a rare disease seen only in women with a breast implant. Because of the low incidence of this disease and the peculiar histological subtype, French authorities, in accordance with the recommendations of an expert group, recommended the implementation of a …

18 years of age Female Phase N/A
J Jean Marc TADIE, MD

Quantitative Computed Tomography for Mortality Risk Stratification in ARDS

Acute respiratory distress syndrome remains a deadly disease with hospital mortality remaining between 40 to 50%. ARDS mortality risk factors have been identified from patient history, common clinical and biological variables in the lung SAFE study. Part of ARDS mortality is attributable to ventilator-induced lung injury (VILI), in relation with …

15 years of age All Phase N/A
J Jean Baptiste FASSIER, MD

Realistic Evaluation of a Job Retention Program After Breast Cancer

Returning to and maintaining employment after cancer is essential for restoring social participation, financial independence and reducing the social costs associated with cancer. Many obstacles that prevent or delay the return to work have been identified. They are associated with the consequences of the disease and treatments such as fatigue, …

18 years of age All Phase N/A

Simplify language using AI